全文获取类型
收费全文 | 7937篇 |
免费 | 324篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 99篇 |
妇产科学 | 99篇 |
基础医学 | 1153篇 |
口腔科学 | 93篇 |
临床医学 | 367篇 |
内科学 | 2199篇 |
皮肤病学 | 147篇 |
神经病学 | 806篇 |
特种医学 | 287篇 |
外科学 | 1490篇 |
综合类 | 18篇 |
预防医学 | 211篇 |
眼科学 | 58篇 |
药学 | 474篇 |
中国医学 | 34篇 |
肿瘤学 | 782篇 |
出版年
2023年 | 33篇 |
2022年 | 65篇 |
2021年 | 106篇 |
2020年 | 67篇 |
2019年 | 81篇 |
2018年 | 129篇 |
2017年 | 99篇 |
2016年 | 116篇 |
2015年 | 138篇 |
2014年 | 188篇 |
2013年 | 237篇 |
2012年 | 359篇 |
2011年 | 462篇 |
2010年 | 266篇 |
2009年 | 262篇 |
2008年 | 467篇 |
2007年 | 470篇 |
2006年 | 490篇 |
2005年 | 534篇 |
2004年 | 538篇 |
2003年 | 590篇 |
2002年 | 604篇 |
2001年 | 105篇 |
2000年 | 96篇 |
1999年 | 125篇 |
1998年 | 171篇 |
1997年 | 158篇 |
1996年 | 122篇 |
1995年 | 111篇 |
1994年 | 127篇 |
1993年 | 109篇 |
1992年 | 72篇 |
1991年 | 64篇 |
1990年 | 61篇 |
1989年 | 62篇 |
1988年 | 68篇 |
1987年 | 44篇 |
1986年 | 36篇 |
1985年 | 29篇 |
1984年 | 40篇 |
1983年 | 43篇 |
1982年 | 50篇 |
1981年 | 46篇 |
1980年 | 43篇 |
1979年 | 27篇 |
1978年 | 34篇 |
1977年 | 14篇 |
1976年 | 20篇 |
1975年 | 19篇 |
1966年 | 18篇 |
排序方式: 共有8349条查询结果,搜索用时 78 毫秒
141.
142.
143.
Impact of aldo‐keto reductase family 1 member B10 on the risk of hepatitis C virus‐related hepatocellular carcinoma
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
144.
Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Yoshio Kiyohara Hisashi Uhara Yoshihiko Ito Noritake Matsumoto Tetsuya Tsuchida Naoya Yamazaki 《The Journal of dermatology》2018,45(4):408-415
A postmarketing surveillance study is ongoing to evaluate nivolumab treatment for Japanese patients with malignant melanoma and accumulate data on all adverse events (AE) and efficacy. In this interim analysis, we evaluated data from approximately 100 Japanese medical institutions obtained from the nivolumab approval date in Japan (4 July 2014) through 3 July 2016. Patients were monitored during the first 12 months of treatment. Nivolumab was administrated by i.v. infusion (2 mg/kg every 3 weeks). A total of 680 and 610 patients were evaluated for safety and efficacy, respectively. The incidences of adverse drug reactions (ADR) and grade 3 or higher ADR were 53.53% and 12.35%, respectively. Predominant ADR included hypothyroidism (11.32%) and abnormal enzyme activity, such as increase of aspartate aminotransferase (7.79%), alanine aminotransferase (6.76%), alkaline phosphatase (6.18%) and γ‐glutamyltransferase (5.44%). Grade 3 or higher ADR of special interest with an incidence of 1% or higher were hepatic function disorder (2.50%), colitis/diarrhea (2.06%) and infusion reaction (1.32%). No cases of encephalitis or venous thromboembolism, other AE of special interest, were observed. The estimated median overall survival was 379 days (95% confidence interval [CI], 290–not reached [NR]) in the overall population, NR (95% CI, 305–NR) for cutaneous melanoma and 340 days (95% CI, 275–NR) for mucosal melanoma. The improvement rate based on the antitumor response at the last evaluation was 22.2% (131/590 patients). No new safety concerns were raised, and serious ADR of special interest were infrequent. Nivolumab showed equivalent efficacy in patients with mucosal melanoma and those with cutaneous melanoma. 相似文献
145.
146.
147.
Gunji Y Nikaidou T Okazumi S Matsubara H Shimada H Nabeya Y Aoki T Makino H Miyazaki S Ochiai T 《Hepato-gastroenterology》2005,52(63):829-832
There has been little research evaluating changes related to tumor cell proliferation between primary and metastatic tumors of gastrointestinal tumors in the same case. We herein report the case of a 50-year-old woman with a gastric gastrointestinal stromal tumor (GIST), who developed metastatic liver tumors three times in the 7 years after proximal gastrectomy for GIST. The primary and all the metastatic liver tumors, except the second, showed fascicular/storiform architecture and the short spindle cell type. The diffuse epithelioid cell proliferation was observed in the second metastatic liver tumor. Although the immunostaining pattern with respect to GIST differentiation markers had been preserved in the primary tumor as well as in all of the metastatic tumors, the latter showed weaker positivity of both Ki-67 and p53 than the primary GIST. The primary tumor showed diffuse positive p53, and the highest value of Ki-67 labeling index (LI) among them. The metastatic liver tumors showed focal, negative or sporadic positive appearances of p53, however, Ki-67 LI were scattering among them. Immunohistochemical assessment of Ki-67 LI and p53 might be useful for evaluating changes related to tumor cell proliferation between primary and metastatic tumors of GISTs. 相似文献
148.
Yoshiyuki Kurata Machiko Oshida Hironori Take Takayasu Furubayashi Hirohisa Nakao Yoshiaki Tomiyama Yoshio Kanayama Nobuo Nagao Yasuto Okubo Takeshi Yonezawa and Seiichiro Tarui 《Vox sanguinis》1989,57(3):199-204
A new method was studied for eliminating HLA class I antigens from the surface of platelets without damaging the cells. Platelets were exposed to an acid solution (pH 3.0) to eliminate the antigenicity of HLA class I antigens. The reduction in antigenicities of HLA class I common antigen and individual HLA class I antigens by acid treatment was marked. Patients' sera which contained multispecific HLA antibodies reacted with PBS-treated platelets, but not with acid-treated platelets. No changes were observed in the antigenicities of glycoprotein Ib or glycoprotein IIb/IIIa. The viability of acid-treated platelets was 83%. Ultrastructural investigations revealed no significant difference between the PBS-treated platelets and acid-treated platelets. The platelet function studies showed that the aggregation of acid-treated platelets induced by various agonists was only slightly reduced compared with PBS-treated platelets. We propose that acid-treated platelets are promising for clinical use in patients refractory to platelet transfusions and may be superior to chloroquine-treated platelets for analysis of the specificity of antiplatelet antibodies. 相似文献
149.
It was reported that neuronal nitric oxide synthase (nNOS) was expressed only in gonadotrophs and folliculo-stellate cells
in the anterior lobe of the pituitary gland. However, recent studies have demonstrated the occurrence of nNOS in the somatotrophs
and lactotrophs. In the present study, we investigated effects of growth hormone-releasing hormone (GHRH), gonadotropin-releasing
hormone (GnRH), and 17β-estradiol on nitric oxide (NO) release in cultured rat anterior pituitary cells in vitro. The NO
2
−
level in the incubation medium of the rat anterior pituitary cells was dependent on the cell density. Pretreatment with 10
μM 17β-estradiol resulted in an increase in medium NO
2
−
level. GHRH and GnRH failed to change medium NO
2
−
levels, but they elicited increases in medium NO
2
−
levels in estrogen-treated cells. The GHRH-induced increase in NO
2
−
level was inhibited by Nχ-nitro-l-arginine methyl ester, a NOS inhibitor. These findings suggest that GnRH and GHRH could activate nNOS in the gonadotrophs
and the somatotrophs, respectively. 相似文献
150.
Fumiki?Yoshihara Miki?Imazu Toshimitsu?Hamasaki Toshihisa?Anzai Satoshi?Yasuda Shin?Ito Haruko?Yamamoto Kazuhiko?Hashimura Yoshio?Yasumura Kiyoshi?Mori Masataka?Watanabe Masanori?Asakura Masafumi?Kitakaze 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2018,32(2):183-190